Contact
searchSearch
HMP Global
Login

Q&As

Philip Harvey, PhD
Q&As
Assessing EMA Outcomes in Xanomeline-Trospium Treatment for Schizophrenia
05/15/2025
In this expert Q&A, Philip D. Harvey, PhD, discusses the Ecological Momentary Assessment (EMA) sub studies that were completed as part of the EMERGENT-5 trial.
In this expert Q&A, Philip D. Harvey, PhD, discusses the Ecological Momentary Assessment (EMA) sub studies that were completed as part of the EMERGENT-5 trial.
In this expert Q&A, Philip D....
05/15/2025
Psych Congress Network
Lucia Cheng
Q&As
Telepsychiatry, Misconceptions, and the Mental Health Power of Gaming
04/30/2025
Lucia Cheng, MD
Psych Congress Elevate 2024 faculty member Lucia Cheng, MD, discusses tips for improving patient engagement in telepsychiatry, misconceptions about virtual care, and advocates for a more nuanced understanding of video gaming's role in...
Psych Congress Elevate 2024 faculty member Lucia Cheng, MD, discusses tips for improving patient engagement in telepsychiatry, misconceptions about virtual care, and advocates for a more nuanced understanding of video gaming's role in...
Psych Congress Elevate 2024...
04/30/2025
Psych Congress Network
headshot of Dr Mohamed Abdelwahab
Q&As
OSA Treatment Outcomes Highlight Impact of Interdisciplinary Care
04/15/2025
Mohamed Abdelwahab, MD, PhD
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD,...
04/15/2025
Psych Congress Network
headshot of Dr Julie Carbray
Q&As
How Clinicians Can Navigate Stimulant vs Nonstimulant Treatments for ADHD
04/11/2025
Julie A. Carbray, PhD, APRN
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute...
04/11/2025
Psych Congress NP Institute
Thomas L. Schwartz, MD
Q&As
A Psychiatrist’s Role in Tackling Sleep-Wake Disorders
03/18/2025
Thomas Schwartz, MD
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores...
03/18/2025
Psych Congress Network
Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
Brittany B. Albright, MD, MPH
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network
Dr Brittany Albright
Q&As
Exploring Anhedonia in Psychiatric Care
03/04/2025
Brittany B. Albright, MD, MPH
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress...
03/04/2025
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas Schwartz, MD
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network
Andrew Penn
Q&As
Psychedelics: New Research, Regulations, and Horizons
10/30/2024
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must...
10/30/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use